Could Eli Lilly’s diabetes drug Jardiance have a positive effect on cardiovascular disease? Recently released results from a large cardiovascular study, reported by Jadiance co-developer Boehringer Ingelheim, indicated that diabetics taking the drug suffered fewer heart attacks and strokes than other diabetics on different blood sugar medicines.
Once-daily Jardiance is an SGLT2 inhibitor that lower blood glucose by block reabsorption in the kidneys. Jardiance was the last of three SGLT2 inhibitors to win FDA approval, following Johnson & Johnson’s Invokana and AstraZeneca’s Farxiga. The positive results that the Lilly drug exhibits could make it a top competitor for the $63 billion annual diabetic drug market in the United States. Jardiance has the potential to become a billion dollar blockbuster as combined annual sales of the other two drugs already top $1.7 billion.
Not everyone is happy about Janrdiance’s potential. Its cardiovascular benefit could help it displace Merck’s Januvia is the top therapy used when metformin therapy fails to control blood sugar. Januvia reached $6 billion in sales in 2014.
Approaches that reduce coronaries and strokes in diabetes patients have gone largely unaddressed. The American Diabetes Association states that hospitalization rates for adult diabetics are 1.8 times higher for heart attacs and 1.5 times higher for stroke than for non diabetics.Januvia’s potential for widespread use stems from a significant unmet need for approaches that reduce heart attack and stroke in diabetes patients.
According to the American Diabetes Association, hospitalization rates for heart attack and stroke are 1.8 times and 1.5 times higher among adult diabetics than non-diabetic adults, respectively. Approximately half of all diabetes-related deaths in the United States result from cardiovascular disease and account for a large portion of the $176 billion spent annual on medical care for diabetes patients.
Eli Lilly and Boehringer plan to release detailed results from their Jardiance cardiovascular study at an industry conference on Sept. 17. Contact us at Prime-Core for more information on the latest health industry trends.